Combination drug therapy for combined hyperlipidemia

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 244-250

  Guyton, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FISH OIL; NICOTINIC ACID;

ARTERIOSCLEROSIS; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HUMAN; HYPERLIPIDEMIA; MUSCLE DISEASE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; FISH OILS; HUMANS; HYPERLIPIDEMIAS; MUSCULAR DISEASES; NIACIN; RHABDOMYOLYSIS; RISK FACTORS;

EID: 0033186429     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0030-z     Document Type: Article

References (49)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
3. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975, 231:360-381.
4. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984, 251:351-374.
5. Carlson LA, Oro L: Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 1973, 18:1-9.
6. Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1996, 1:195-202.
7. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
8. Knopp RH, Ginsberg J, Albers JJ, et al.: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985, 34:642-650.
9. Davignon J, Roederer G, Montigny M, et al.: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994, 73:339-345.
10. McKenney JM, Proctor JD, Harris S, Chinchili VM: A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc 1994, 271:672-677.
11. Guyton JR, Goldberg AC, Kreisberg RA, et al.: Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998, 82:737-743.
12. Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998, 82:82U-84U.
13. Capuzzi DM, Guyton JR, Morgan JM, et al.: Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998, 82:74U-81U.
14. Merck & Company: Product information for Mevacor (lovastatin). In Physician's Desk Reference. Montvale, New Jersey: Medical Economics Company; 1996:1701.
15. Reaven P, Witztum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988, 109: 597-598.
16. Cooke HM: Lovastatin- and niacin-induced rhabdomyolysis. Hospital Pharmacy 1994, 29:33-34.
17. Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978, 40:1069-1118.
18. Parke-Davis: Product information for Lopid (gemfibrozil). In Physician's Desk Reference. Montvale, New Jersey: Medical Economics Company; 1999.
19. Rubins HB, Robins SJ, Collins D: The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol 1996, 78:572-575.
20. Glueck CJ, Oakes N, Speirs J, et al.: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992, 70: 1-9.
21. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc 1990, 264:71-75.
22. Smith AF, Macfie WG, Oliver MF: Clofibrate, serum enzymes, and muscle pain. Br Med J 1970, 2:86-88.
23. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 1991, 151:1873-1874.
24. Harris WS: Dietary fish oil and blood lipids. Curr Opin Lipidol 1996, 7:3-7.
25. Sprecher DL, Abrams J, Allen JW, et al.: Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994, 120:537-543.
26. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988, 109: 25-32.
27. Gordon DJ, Knoke J, Probstfield JL, et al.: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986, 74:1217-1225.
28. Brown BG, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
29. Miettinen TA, Puska P, Gylling H, et al.: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308-1312.
30. Pasternak RC, Brown LE, Stone PH, et al.: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med 1996, 125:529-540.
31. Sacks FM, Pasternak RC, Gibson CM, et al.: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994, 344:1182-1186.
32. Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
33. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 1990, 264:3007-3012.
34. Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 1987, 257:3233-3240.
35. Brown BG, Bardsley J, Poulin D, et al.: Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997, 80:111-115.
36. Jacobson TA, Chin MM, Fromell GJ, et al.: Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994, 74:149-154.
37. O'Keefe JH, Jr., Harris WS, Nelson J, Windsor SL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995, 76:480-484.
38. Gardner SF, Schneider EF, Granberry MC, Carter IR: Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996, 16:419-423.
39. Gardner SF, Marx MA, White LM, et al.: Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother 1997, 31:677-682.
40. Vacek JL, Dittmeier G, Chiarelli T, et al.: Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol 1995, 76:182-184.
41. Wiklund O, Angelin B, Bergman M, et al.: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993, 94:13-20.
42. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al.: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997, 80:608-613.
43. Ellen RL, McPherson R: Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998, 81: 60B-65B.
44. Iliadis EA, Rosenson RS: Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999, 22:25-28.
45. Zambon D, Ros E, Rodriguez-Villar C, et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 1999, 48:47-54.
46. Kayikcioglu M, Ozerkan F, Soydan I: Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999, 83:1135-1137.
47. Contacos C, Barter PJ, Sullivan DR: Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993, 13:1755-1762.
48. Davidson MH, Macariola-Coad JR, McDonald AM, et al.: Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol 1997, 80:797-798.
49. Spencer GA, Wirebaugh S, Whitney EJ: Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol 1996, 36:696-700.